AIM: To report 24 years of pre-treatment biopsy and surgical experience in primary liver tumours in children. METHODS: Between 1979 and 2003, 53 children presented with a primary liver tumour of whom 48 who underwent surgical resection were evaluated (two died, two were unresectable, and one was transplanted). Biopsy data, per- and post-operative complications, mortality, and survival were retrospectively reviewed. RESULTS: Benign tumours were diagnosed in eight patients. Surgical resection for a malignant tumour was performed in 40 patients (26 hepatoblastomas (HB), eight hepatocellular carcinomas (HCC) (four had fibrolamellar HCC), three rhabdomyosarcomas (RMS), one neuroblastoma, one non-hodgkin lymphoma (NHL), and one teratoma). Primary resection was performed in one HB, and four HCCs. The cumulative survival without evidence of disease was 73% for HB (median 7 years) and 88% for HCC (median 3.5 years). CONCLUSION: The treatment results are comparable with those of larger international series except for HCC. The existing diagnostic pitfalls in differentiating between the various liver malignancies justify the use of a diagnostic biopsy.
AIM: To report 24 years of pre-treatment biopsy and surgical experience in primary liver tumours in children. METHODS: Between 1979 and 2003, 53 children presented with a primary liver tumour of whom 48 who underwent surgical resection were evaluated (two died, two were unresectable, and one was transplanted). Biopsy data, per- and post-operative complications, mortality, and survival were retrospectively reviewed. RESULTS:Benign tumours were diagnosed in eight patients. Surgical resection for a malignant tumour was performed in 40 patients (26 hepatoblastomas (HB), eight hepatocellular carcinomas (HCC) (four had fibrolamellar HCC), three rhabdomyosarcomas (RMS), one neuroblastoma, one non-hodgkin lymphoma (NHL), and one teratoma). Primary resection was performed in one HB, and four HCCs. The cumulative survival without evidence of disease was 73% for HB (median 7 years) and 88% for HCC (median 3.5 years). CONCLUSION: The treatment results are comparable with those of larger international series except for HCC. The existing diagnostic pitfalls in differentiating between the various liver malignancies justify the use of a diagnostic biopsy.
Authors: Linde A D Busweiler; Marc H W A Wijnen; Jim C H Wilde; Egbert Sieders; Sheila E J Terwisscha van Scheltinga; L W Ernest van Heurn; Joseph Ziros; Roel Bakx; Hugo A Heij Journal: Pediatr Surg Int Date: 2016-10-11 Impact factor: 1.827
Authors: Christopher B Weldon; Arin L Madenci; Gregory M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; Sarangarajan Ranganathan; Dolores H López-Terrada; Milton J Finegold; Marcio H Malogolowkin; Jin Piao; Li Huang; Mark D Krailo; Rebecka L Meyers; Howard M Katzenstein Journal: J Pediatr Surg Date: 2019-05-11 Impact factor: 2.545
Authors: Rebecka L Meyers; Jon R Rowland; Mark Krailo; Zhengjia Chen; Howard M Katzenstein; Marcio H Malogolowkin Journal: Pediatr Blood Cancer Date: 2009-12 Impact factor: 3.167
Authors: Alexander Moll; Alexander Krenauer; Uta Bierbach; Holger Till; Wolfgang Hirsch; Ivo Leuschner; Nicole Schmitz; Christian Wittekind; Thomas Aigner Journal: Diagn Pathol Date: 2009-11-12 Impact factor: 2.644